title: Current clinical challenges in prostate cancer.
abstract: Prostate cancer is the most common malignancy and the second leading cause of cancer death in men in the United States. Close to $12 billion are spent annually on the treatment of prostate cancer in the US alone. Yet still there remain tremendous controversies and challenges that exist in all facets of the disease. This review and discussion will focus on issues and challenges for clinicians and patients diagnosed with the disease. Appropriate risk stratification for men with newly diagnosed prostate cancer is an appropriate first step for all patients. Once risk-stratified, for those with low-risk of death, it is increasingly recognized that overtreatment creates an unnecessary burden for many patients. This is particularly evident when put in the context of competing comorbidities in an elderly population. For those with advanced or high-risk localized disease, under-treatment remains too common. For those with a high-risk of recurrence or failure following primary treatment, adjuvant or salvage therapies are an option, but how and when to best deploy these treatments are controversial. Recently, tremendous progress has been made for those with advanced disease, in particular those with metastatic castrate-resistant prostate cancer (mCRPC). Within the last 4 years, five novel FDA approved agents, acting through distinct mechanisms have been FDA approved for mCRPC. With the introduction of these new agents a host of new challenges have arisen. Timing, sequencing and combinations of these novel agents are welcomed challenges when compared with the lack of available therapies just a few years ago. In this summary of current clinical challenges in prostate cancer we review critical recent studies that have created or shifted the current paradigms of treatment for prostate cancer. We will also highlight ongoing issues that continue to challenge our field.
authors.affiliation: Department of Urology (JLS, OS) and Department of Medicine (BL, OS) Tulane University School of Medicine, New Orleans, LA and Department of Medical Oncology & Experimental Therapeutics (SKP) City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA.
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Silberstein
authors.affiliation: Department of Urology (JLS, OS) and Department of Medicine (BL, OS) Tulane University School of Medicine, New Orleans, LA and Department of Medical Oncology & Experimental Therapeutics (SKP) City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA.
authors.forename: Sumanta Kumar
authors.initials: SK
authors.lastname: Pal
authors.affiliation: Department of Urology (JLS, OS) and Department of Medicine (BL, OS) Tulane University School of Medicine, New Orleans, LA and Department of Medical Oncology & Experimental Therapeutics (SKP) City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Lewis
authors.affiliation: Department of Urology (JLS, OS) and Department of Medicine (BL, OS) Tulane University School of Medicine, New Orleans, LA and Department of Medical Oncology & Experimental Therapeutics (SKP) City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA.
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
keywords: Prostate neoplasms; active surveillance (AS); castrate-resistance; chemotherapy; hormone therapy; survival
references.citation: J Clin Oncol. 2011 Jun 1;29(16):2185-90
references.pmid: 21464416
references.citation: Cancer Res. 2013 Jan 15;73(2):483-9
references.pmid: 23117885
references.citation: Mol Endocrinol. 1993 Dec;7(12):1541-50
references.pmid: 8145761
references.citation: J Natl Cancer Inst. 1998 May 20;90(10):766-71
references.pmid: 9605647
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: Eur Urol. 2010 Dec;58(6):831-5
references.pmid: 20800964
references.citation: JAMA. 2003 May 28;289(20):2695-700
references.pmid: 12771116
references.citation: Lancet. 2009 Jan 24;373(9660):301-8
references.pmid: 19091394
references.citation: Ann Oncol. 2013 Jul;24(7):1802-7
references.pmid: 23585511
references.citation: J Urol. 2005 Jun;173(6):1938-42
references.pmid: 15879786
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1117-23
references.pmid: 20124165
references.citation: BJU Int. 2011 Feb;107(4):576-84
references.pmid: 20735387
references.citation: Eur Urol. 2014 Jan;65(1):30-6
references.pmid: 23849416
references.citation: N Engl J Med. 2012 Sep 27;367(13):1187-97
references.pmid: 22894553
references.citation: J Urol. 2011 Mar;185(3):869-75
references.pmid: 21239008
references.citation: In Vivo. 1994 May-Jun;8(3):439-43
references.pmid: 7803731
references.citation: J Urol. 2004 Mar;171(3):1141-7
references.pmid: 14767288
references.citation: Can Urol Assoc J. 2012 Oct;6(5):367-73
references.pmid: 23093629
references.citation: N Engl J Med. 2013 Apr 4;368(14):1314-25
references.pmid: 23550669
references.citation: N Engl J Med. 2004 Oct 7;351(15):1513-20
references.pmid: 15470214
references.citation: Lancet. 2010 Oct 2;376(9747):1147-54
references.pmid: 20888992
references.citation: Lancet. 2012 Jan 7;379(9810):39-46
references.pmid: 22093187
references.citation: JAMA. 1999 May 5;281(17):1591-7
references.pmid: 10235151
references.citation: Eur Urol. 2009 Jan;55(1):1-8
references.pmid: 18805628
references.citation: J Clin Oncol. 2010 Jan 1;28(1):126-31
references.pmid: 19917860
references.citation: N Engl J Med. 2012 Sep 6;367(10):945-6
references.pmid: 22931264
references.citation: Clin Cancer Res. 2013 May 1;19(9):2442-50
references.pmid: 23515404
references.citation: J Urol. 2006 Jan;175(1):99-103
references.pmid: 16406881
references.citation: Lancet Oncol. 2006 Jun;7(6):472-9
references.pmid: 16750497
references.citation: J Clin Oncol. 2006 Apr 20;24(12):1868-76
references.pmid: 16622261
references.citation: Ann Oncol. 2013 Jul;24(7):1807-12
references.pmid: 23576708
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3576-81
references.pmid: 17704404
references.citation: Eur Urol. 2008 Dec;54(6):1297-305
references.pmid: 18342430
references.citation: N Engl J Med. 2012 Jul 19;367(3):203-13
references.pmid: 22808955
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: JAMA. 2013 Jun 26;309(24):2587-95
references.pmid: 23800935
references.citation: J Urol. 1996 Jul;156(1):127-32
references.pmid: 8648773
references.citation: Eur Urol. 2012 May;61(5):1019-24
references.pmid: 22336380
references.citation: Eur Urol. 2013 Nov;64(5):713-9
references.pmid: 23787357
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: J Urol. 2009 Mar;181(3):956-62
references.pmid: 19167731
references.citation: Ann Oncol. 2012 Nov;23 (11):2943-7
references.pmid: 22771826
references.citation: J Urol. 2011 Feb;185(2):477-82
references.pmid: 21167529
references.citation: Cancer. 2008 Jun 15;112(12):2664-70
references.pmid: 18433013
references.citation: N Engl J Med. 2012 Sep 6;367(10):895-903
references.pmid: 22931259
references.citation: Cancer. 2003 Feb 1;97(3 Suppl):758-71
references.pmid: 12548573
references.citation: N Engl J Med. 2013 Jan 10;368(2):138-48
references.pmid: 23228172
references.citation: Lancet. 2012 Dec 8;380(9858):2018-27
references.pmid: 23084481
references.citation: South Med J. 1999 Apr;92(4):415-6
references.pmid: 10219363
references.citation: Lancet. 2010 Apr 24;375(9724):1437-46
references.pmid: 20398925
references.citation: J Clin Endocrinol Metab. 2012 Feb;97(2):507-16
references.pmid: 22170708
references.citation: N Engl J Med. 2013 Jul 18;369(3):213-23
references.pmid: 23863050
references.citation: J Clin Oncol. 2011 Jul 10;29(20):2795-800
references.pmid: 21632511
references.citation: J Urol. 2008 Mar;179(3):901-4; discussion 904-5
references.pmid: 18207195
references.citation: JAMA. 2005 May 4;293(17):2095-101
references.pmid: 15870412
references.citation: J Urol. 2007 Aug;178(2):493-9; discussion 499
references.pmid: 17561152
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862
references.citation: J Urol. 2004 Apr;171(4):1513-9
references.pmid: 15017210
references.citation: Onco Targets Ther. 2013 Jun 17;6:725-32
references.pmid: 23836984
references.citation: Prostate Cancer Prostatic Dis. 2006;9(3):270-4
references.pmid: 16770340
references.citation: BJU Int. 2011 Mar;107(5):765-70
references.pmid: 20875089
references.citation: N Engl J Med. 2011 May 5;364(18):1708-17
references.pmid: 21542742
references.citation: N Engl J Med. 1997 Jul 31;337(5):295-300
references.pmid: 9233866